Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1719-1726

  Uchida, Yasuo ^a   Ohtsuki, Sumio ^b   Terasaki, Tetsuya ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PENTETRAZOLE; PHENYTOIN; VERAPAMIL; ANTICONVULSIVE AGENT; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; EPILEPSY; IN VITRO STUDY; IN VIVO STUDY; KINDLING; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; TISSUE DISTRIBUTION; ANIMAL; BIOSYNTHESIS; BLOOD; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; METABOLISM; VASCULARIZATION;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; EPILEPSY; MALE; MEMBRANE PROTEINS; MICE; P-GLYCOPROTEIN; PENTYLENETETRAZOLE; PHENYTOIN; PROTEOMICS; VERAPAMIL;

EID: 84907426957     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059055     Document Type: Article

References (32)

1. Adachi Y, Suzuki H, and Sugiyama Y (2001) Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18:1660-1668.
2. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, and Elmquist WF (2012) Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 40:1164-1169.
3. Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, and Hosoya K (2011) Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharideinduced inflammation and additive inhibitory effect of cefmetazole. Fluids Barriers CNS 8:24.
4. Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano H, Maeda J, Okubo Y, and Suhara T (2010) Positron emission tomography measurement of dopamine D2receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 71:1131-1137.
5. Clarke DF, Roberts W, Daraksan M, Dupuis A, McCabe J, Wood H, Snead OC, 3rd, and Weiss SK (2005) The prevalence of autistic spectrum disorder in children surveyed in a tertiary care epilepsy clinic. Epilepsia 46:1970-1977.
6. Croll SD, Goodman JH, and Scharfman HE (2004) Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. Adv Exp Med Biol 548:57-68.
7. De Sarro A, Naccari F, and De Sarro G (1999) Enhanced susceptibility of pentylenetetrazole kindled mice to quinolone effects. Int J Antimicrob Agents 12:239-244.
8. Feldmann M, Asselin MC, Liu J, Wang S, McMahon A, Anton-Rodriguez J, Walker M, Symms M, Brown G, and Hinz R, et al. (2013) P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 12: 777-785.
9. Hawkins BT, Sykes DB, and Miller DS (2010) Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor. J Neurosci 30: 1417-1425.
10. Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559.
11. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel insilico peptide selection criteria. Pharm Res 25:1469-1483.
12. King JT, Jr and LaMotte CC (1989) El mouse as a model of focal epilepsy: a review. Epilepsia 30:257-265.
13. Liu X, Yang Z, Yang J, and Yang H (2007) Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 53:657-663.
14. Löscher W and Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602.
15. Lothman EW, Williamson JM, and VanLandingham KE (1991) Intraperitoneal phenytoin suppresses kindled responses: effects on motor and electrographic seizures. Epilepsy Res 9: 11-18.
16. Meidenbauer JJ, Mantis JG, and Seyfried TN (2011) The EL mouse: a natural model of autism and epilepsy. Epilepsia 52:347-357.
17. Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the bloodbrain barrier. Trends Pharmacol Sci 31:246-254.
18. Ohtsuki S, Yamaguchi H, Asashima T, and Terasaki T (2007) Establishing a method to isolate rat brain capillary endothelial cells by magnetic cell sorting and dominant mRNA expression of multidrug resistance-associated protein 1 and 4 in highly purified rat brain capillary endothelial cells. Pharm Res 24:688-694.
19. Rigau V, Morin M, Rousset MC, de Bock F, Lebrun A, Coubes P, Picot MC, Baldy-Moulinier M, Bockaert J, and Crespel A, et al. (2007) Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 130:1942-1956.
20. Shawahna R, Uchida Y, Declèves X, Ohtsuki S, Yousif S, Dauchy S, Jacob A, Chassoux F, Daumas-Duport C, and Couraud PO, et al. (2011) Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 8:1332-1341.
21. Suzuki J (1976) Paroxysmal discharges in the electroencephalogram of the E1 mouse. Experientia 32:336-338.
22. Suzuki J (2013) Neuronal mechanism of epileptogenesis in EL mouse. Proc Jpn Acad, Ser B, Phys Biol Sci 89:270-280.
23. Syvänen S and Eriksson J (2013) Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci 4:225-237.
24. Uchida Y, Ohtsuki S, Kamiie J, and Terasaki T (2011a) Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 339:579-588.
25. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, and Terasaki T (2011b) Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 117:333-345.
26. Uchida Y, Tachikawa M, Obuchi W, Hoshi Y, Tomioka Y, Ohtsuki S, and Terasaki T (2013) A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for interstrain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 10:21.
27. Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, and Terasaki T (2014) Bloodbrain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys. J Pharmacol Exp Ther 350:578-588.
28. Urquhart BL, Tirona RG, and Kim RB (2007) Nuclear receptors and the regulation of drugmetabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566-578.
29. Vezzani A, French J, Bartfai T, and Baram TZ (2011) The role of inflammation in epilepsy. Nat Rev Neurol 7:31-40.
30. Vezzani A and Granata T (2005) Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46:1724-1743.
31. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, and LeCluyse E (2004) Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279:29295-29301.
32. Wen T, Liu YC, Yang HW, Liu HY, Liu XD, Wang GJ, and Xie L (2008) Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J Neurol Sci 270:99-106.